Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
Varenicline Versus Nicotine Replacement for Methadone-Maintained Smokers
RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit smoking.
PURPOSE: This randomized clinical trial is studying varenicline to see how well it works compared with the nicotine patch given together with nicotine gum in helping smokers in a methadone treatment program stop smoking.
調査の概要
詳細な説明
OBJECTIVES:
Primary
- To determine whether varenicline, a nicotine receptor partial agonist, leads to a higher rate of smoking cessation than combination nicotine replacement therapy with nicotine patch prescription plus ad libitum nicotine gum delivery in methadone-maintained smokers.
Secondary
- To test the effects of the treatments on smoking urges, withdrawal symptoms, and reinforcing effects of smoking.
- To test the effects of the treatments on methadone treatment outcomes, including retention in methadone maintenance, methadone dose changes, and continued use of illicit drugs as measured by urine toxicologies.
OUTLINE: This is a multicenter study. Patients are stratified based on gender and level of nicotine dependence. Patients are randomized to 1 of 3 intervention arms.
At baseline, all patients receive a minimal behavioral intervention using a 3-minute, simple smoking cessation counseling strategy, a self-help manual, and a telephone quit-line number.
- Arm I (varenicline): Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
- Arm II (placebo): Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
- Arm III (nicotine patch/gum): Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.
Patients complete a brief interview over 10-15 minutes at 2 weeks and monthly during months 1-5. They complete a longer interview over 45 minutes at months 6 and 12 and provide breath samples (for carbon monoxide monitoring) and urine samples (for cotinine testing).
NOTE: Smoking cessation may prevent certain smoking-related illnesses, including cancer.
PROJECTED ACCRUAL: A total of 602 patients (258 receiving varenicline, 258 receiving nicotine replacement therapy, and 86 receiving placebo) will be accrued for this study.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02903
- Rhode Island Hospital Comprehensive Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
INCLUSION CRITERIA
- Current and regular cigarette smokers (over 10 cigarettes/day for the past 3 months)
Interested in quitting smoking
- Willing to set a quit date 7 days after baseline assessment
Participating in 1 of 5 methadone maintenance treatment programs across Rhode Island at any of the following institutions:
- Codac, Inc. (with two independent sites)
- Addiction Recovery Institute
- Center for Treatment and Recovery
- Discovery House
- Has received methadone for at least the past month
EXCLUSION CRITERIA
- Pregnant or nursing (Must have negative pregnancy test)
- Non-English speaking
- No personal telephone or does not live close to a relative or neighbor with a telephone
- Unwilling to make their methadone dose and methadone maintenance treatment program urine toxicologies available for review
- Unvailable for this study for the next 12 months
- Suffering from any unstable medical condition which would preclude the use of the nicotine patch (e.g., unstable angina or uncontrolled hypertension)
- Active skin condition (e.g., psoriasis)
- History of skin allergy
- History of a suicide attempt
- Working as pilots, drivers, or operators of heavy machinery
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No concurrent insulin or blood thinners
- No concurrent smokeless tobacco, nicotine replacement therapy, or other smoking cessation treatment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm I
Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
|
Given orally
|
|
プラセボコンパレーター:Arm II
Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.
|
経口投与
|
|
アクティブコンパレータ:Arm III
Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks.
Patients also receive nicotine gum to quell breakthrough urges.
Patients may stop treatment when a comfortable level of smoking abstinence is reached.
|
Given transdermally and orally
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Self- Reported 7-day Abstinence
時間枠:6 Months
|
Number of participants with self-reported, 7-day abstinence at 6-months
|
6 Months
|
|
Carbon Monoxide (CO)-Confirmed 7-day Abstinence
時間枠:6-Months
|
Number of participants reporting 7-day abstinence at 6-months, confirmed with CO measurement.
|
6-Months
|
|
Rates of Smoking Cessation Continuous From First Quit Day to 6 Months
時間枠:6-Months
|
Number of participants who self-reported continuous abstinence from their initial quit day (study day 14) to 6 Months
|
6-Months
|
|
Self-reported 7-day Abstinence
時間枠:12 Months
|
Number of participants with self-reported 7-day abstinence at 12-months
|
12 Months
|
|
CO-confirmed 7-day Abstinence
時間枠:12 Months
|
Number of participants reporting 7-day abstinence at 12-months, confirmed with CO measurement.
|
12 Months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in Smoking Urges
時間枠:6 months
|
Smoking urges was measured on a 0 (not at all) - 100 (strongest feeling possible) scale.
Higher values represent greater urge to smoke.
Change in smoking urges was calculated as Follow-up score (6 month) - Baseline Score.
|
6 months
|
|
Withdrawal Symptoms
時間枠:6 months
|
Withdrawal Symptoms were measured using a modified version of the Minnesota Behavior Rating Scale.
The scale asked subjects to rate their smoking withdrawal symptoms over the previous 24 hours on a scale from 0 (none) to 4 (severe).
Higher values indicate more severe withdrawal symptoms.
Change in withdrawal symptoms was calculated as Follow-up score (6 month) - Baseline Score.
|
6 months
|
|
Retention in Methadone Maintenance
時間枠:12 months
|
12 months
|
|
|
Methadone Dose Changes
時間枠:12 months
|
12 months
|
|
|
Use of Illicit Drugs as Measured by Urine Toxicologies
時間枠:12 months
|
12 months
|
|
|
Reinforcing Effects of Smoking
時間枠:6 months
|
Reinforcing effects of smoking was measured using the modified version of the Cigarette Evaluation Questionnaire.
Participants were asked to indicate on a 12-item scale how smoking made them feel in the prior 30 days on a scale from 1 (Not at all) to 7 (Extremely).
Higher values indicated that smoking was a more positive experience for 10 of 12 items.
Two items were reverse coded.
Change in reinforcing effects of smoking was calculated as Follow-up score (6 month) - Baseline Score.
|
6 months
|
|
Change in Cigarettes Per Day
時間枠:6-Months
|
Change in mean cigarettes per day
|
6-Months
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:Michael Stein, MD、Butler Hospital
出版物と役立つリンク
一般刊行物
- Stein MD, Caviness CM, Kurth ME, Audet D, Olson J, Anderson BJ. Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. Drug Alcohol Depend. 2013 Dec 1;133(2):486-93. doi: 10.1016/j.drugalcdep.2013.07.005. Epub 2013 Aug 14.
- de Dios MA, Anderson BJ, Caviness CM, Stein M. Intimate partner violence among individuals in methadone maintenance treatment. Subst Abus. 2014;35(2):190-3. doi: 10.1080/08897077.2013.835764.
- Caviness CM, Bird JL, Anderson BJ, Abrantes AM, Stein MD. Minimum recommended physical activity, and perceived barriers and benefits of exercise in methadone maintained persons. J Subst Abuse Treat. 2013 Apr;44(4):457-62. doi: 10.1016/j.jsat.2012.10.002. Epub 2012 Nov 28.
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 精神障害
- 化学誘発性疾患
- 消化器系疾患
- 物質関連障害
- 気道疾患
- 新生物
- 肺疾患
- 泌尿器科の新生物
- 泌尿生殖器腫瘍
- 部位別新生物
- 泌尿器疾患
- 膀胱疾患
- 子宮腫瘍
- 性器腫瘍、女性
- 子宮頸部疾患
- 子宮の病気
- 内分泌系疾患
- 消化器腫瘍
- 消化器系腫瘍
- 消化器疾患
- 胃の病気
- 内分泌腺腫瘍
- 肝疾患
- 気道腫瘍
- 胸部腫瘍
- 頭頸部腫瘍
- 食道疾患
- 膵臓の病気
- 子宮頸部腫瘍
- 胃の新生物
- 肺新生物
- タバコ使用障害
- 膀胱腫瘍
- 膵臓の新生物
- 肝腫瘍
- 食道腫瘍
- 薬の生理作用
- 神経伝達物質のエージェント
- 薬理作用の分子機構
- 自律神経剤
- 末梢神経系エージェント
- コリン作動薬
- 神経節刺激薬
- ニコチン作動薬
- コリン作動薬
- ニコチン
- バレニクリン
その他の研究ID番号
- CDR0000616663
- R01CA129226 (米国 NIH グラント/契約)
- BUTLER-0807-004
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。